Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2024

Open Access 17-02-2024 | Lymphoma | Review

Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application

Authors: Zongyao Huang, Yao Fu, Hong Yang, Yehan Zhou, Min Shi, Qingyun Li, Weiping Liu, Junheng Liang, Liuqing Zhu, Sheng Qin, Huangming Hong, Yang Liu

Published in: Molecular Cancer | Issue 1/2024

Login to get access

Abstract

T-cell lymphoma is a highly invasive tumor with significant heterogeneity. Invasive tissue biopsy is the gold standard for acquiring molecular data and categorizing lymphoma patients into genetic subtypes. However, surgical intervention is unfeasible for patients who are critically ill, have unresectable tumors, or demonstrate low compliance, making tissue biopsies inaccessible to these patients. A critical need for a minimally invasive approach in T-cell lymphoma is evident, particularly in the areas of early diagnosis, prognostic monitoring, treatment response, and drug resistance. Therefore, the clinical application of liquid biopsy techniques has gained significant attention in T-cell lymphoma. Moreover, liquid biopsy requires fewer samples, exhibits good reproducibility, and enables real-time monitoring at molecular levels, thereby facilitating personalized health care. In this review, we provide a comprehensive overview of the current liquid biopsy biomarkers used for T-cell lymphoma, focusing on circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), Epstein-Barr virus (EBV) DNA, antibodies, and cytokines. Additionally, we discuss their clinical application, detection methodologies, ongoing clinical trials, and the challenges faced in the field of liquid biopsy.
Literature
1.
Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y, et al. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. Lancet Reg Health West Pac. 2021;10:100126.PubMedPubMedCentralCrossRef
2.
Iqbal J, Wilcox R, Naushad H, Rohr J, Heavican TB, Wang C, et al. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis? (1532–1681 (Electronic)).
3.
4.
5.
6.
Lee HJ, Im Jg Fau - Goo JM, Goo Jm Fau - Kim KW, Kim Kw Fau - Choi BI, Choi Bi Fau - Chang KH, Chang Kh Fau - Han JK, et al. Peripheral T-cell lymphoma: spectrum of imaging findings with clinical and pathologic features. (0271–5333 (Print)).
7.
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. (1546–170X (Electronic)).
8.
Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, et al. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. (1949–2553 (Electronic)).
9.
Scherer F. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. (0080–0015 (Print)).
10.
Sardarabadi P, Kojabad AA, Jafari D, Liu CH. Liquid biopsy-based biosensors for MRD detection and treatment monitoring in Non-Small Cell Lung Cancer (NSCLC). Biosensors (Basel). 2021;11(10):394.PubMedCrossRef
11.
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. (1756–8722 (Electronic)).
12.
Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. (1476–4598 (Electronic)).
13.
Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, et al. Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. (2159–8290 (Electronic)).
14.
Fitzpatrick A, Iravani MA-O, Mills AA-OX, Childs L, Alaguthurai T, Clifford A, et al. Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. (1557–3265 (Electronic)).
15.
Wu H, Ji H, Yang W, Zhang M, Guo Y, Li B, et al. Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers. (1471–2407 (Electronic)).
16.
Kaczor-Urbanowicz KE, Wei F, Rao SL, Kim J, Shin H, Cheng J, et al. Clinical validity of saliva and novel technology for cancer detection. (1879–2561 (Electronic)).
17.
Freitas AA-O, Causin RA-O, Varuzza MA-O, Calfa SA-O, Hidalgo Filho CMT, Komoto TA-O, et al. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. LID. https://​doi.​org/​10.​3390/​ijms23179952. LID - 9952. (1422–0067 (Electronic)).
18.
Rzhevskiy AA-O, Kapitannikova AY, Vasilescu SA, Karashaeva TA-O, Razavi Bazaz SA-O, Taratkin MS, et al. Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics. LID - https://​doi.​org/​10.​3390/​cancers14143364. LID - 3364. (2072–6694 (Print)).
19.
Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. (1573–7233 (Electronic)).
20.
Tomar U, Grover N, Tomar S, Bhalla K, Singh S. Liquid biopsy and its significance in tumour - Detection in the field of pathology. J Oral Maxillofac Pathol. 2023;27(1):195–200.PubMedPubMedCentralCrossRef
21.
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.
22.
Ma S, Zhou M, Xu Y, Gu X, Zou M, Abudushalamu G, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. (1476–4598 (Electronic)).
23.
Alix-Panabières C, Bartkowiak K, Pantel K. Functional studies on circulating and disseminated tumor cells in carcinoma patients. (1878–0261 (Electronic)).
24.
Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden JA-O, Martins-Filho SN, et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. (1476–5594 (Electronic)).
25.
26.
Sakata-Yanagimoto M, Nakamoto-Matsubara R, Komori D, Nguyen TB, Hattori K, Nanmoku T, et al. Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. Ann Hematol. 2017;96(9):1471–5.PubMedCrossRef
27.
Hayashida M, Maekawa F, Chagi Y, Iioka F, Kobashi Y, Watanabe M, et al. Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2020;61(10):2389–98.PubMedCrossRef
28.
Ottolini B, Nawaz N, Trethewey CS, Mamand S, Allchin RL, Dillon R, et al. Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. Blood Adv. 2020;4(11):2392–403.PubMedPubMedCentralCrossRef
29.
Li Q, Zhang W, Li J, Xiong J, Liu J, Chen T, et al. Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. Biomark Res. 2020;8:27.PubMedPubMedCentralCrossRef
30.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016;175(5):841–50.PubMedPubMedCentralCrossRef
31.
Zhang W, Wang W, Han X, Gan Y, Qian L, Zhang Y, et al. Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas. Int J Lab Hematol. 2021;43(5):1041–9.PubMedCrossRef
32.
Miljkovic MD, Melani C, Pittaluga S, Lakhotia R, Lucas N, Jacob A, et al. Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL. Blood Adv. 2021;5(20):4198–210.PubMedPubMedCentral
33.
Chen F, Pang D, Guo H, Jiang X, Liu S, Huang L, et al. Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population. Cancer Manag Res. 2020;12:3003–12.PubMedPubMedCentralCrossRef
34.
Qi F, Cao Z, Chen B, Chai Y, Lin J, Ye J, et al. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring. Blood Adv. 2021;5(11):2505–14.PubMedPubMedCentralCrossRef
35.
Kim SJ, Kim YJ, Yoon SE, Ryu KJ, Park B, Park D, et al. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. Cancer Res Treat. 2023;55(1):291–303.PubMedCrossRef
36.
Cortés JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol. 2016;23(4):434–43.PubMedCrossRef
37.
Chiba S, Enami T, Ogawa S, Sakata-Yanagimoto M. G17V RHOA: Genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells. Small GTPases. 2015;6(2):100–3.PubMedPubMedCentralCrossRef
38.
Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371–5.PubMedCrossRef
39.
Sakata-Yanagimoto M, Nakamoto-Matsubara R, Komori D, Nguyen TB, Hattori K, Nanmoku T, et al. Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. Ann Hematol. 2017;96(9):1471–5.PubMedCrossRef
40.
Ottolini B, Nawaz N, Trethewey CS, Mamand S, Allchin RL, Dillon R, et al. Multiple mutations at exon 2 of RHOA detected in plasm a from patients with peripheral T-cell lymphoma. Blood Adv. 2020;4(11):2392–403.
41.
Qi F, Cao Z, Chen B, Chai Y, Lin J, Ye J, et al. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring. Blood Adv. 2021;5(11):2505–14.PubMedPubMedCentralCrossRef
42.
Li Q, Zhang W, Li J, Xiong J, Liu J, Chen T, et al. Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. Biomark Res. 2020;8:27.PubMedPubMedCentralCrossRef
43.
Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017;123(7):1174–83.PubMedCrossRef
44.
Kim SJ, Kim YJ, Yoon SE, Ryu KJ, Park B, Park D, et al. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. Cancer Res Treat. 2023;55(1):291–303.PubMedCrossRef
45.
Kwok M, Wu SP, Mo C, Summers T, Roschewski M. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas. Curr Treat Options Oncol. 2016;17(9):47.PubMedCrossRef
46.
Chase ML, Armand P. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Br J Haematol. 2018;180(2):177–88.PubMedCrossRef
47.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016;175(5):841–50.PubMedPubMedCentralCrossRef
48.
Miljkovic MD, Melani C, Pittaluga S, Lakhotia R, Lucas N, Jacob A, et al. Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL. Blood Adv. 2021;5(20):4198–210.PubMedPubMedCentral
49.
Cirillo M, Craig AFM, Borchmann S, Kurtz DM. Liquid biopsy in lymphoma: Molecular methods and clinical applications. (1532–1967 (Electronic)).
50.
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. (1546–1696 (Electronic)).
51.
Hayashida M, Maekawa F, Chagi Y, Iioka F, Kobashi Y, Watanabe MA-O, et al. Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma. (1029–2403 (Electronic)).
52.
53.
Rossi DA-O, Kurtz DM, Roschewski M, Cavalli F, Zucca E, Wilson WH. The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA. (1099–1069 (Electronic)).
54.
Zhang S, Zhou D, Li S, Bai Y, Huang B, Han J, et al. Performance of ImproGene cfDNA blood collection tubes for mutation analysis in cancer patients. Scand J Clin Lab Invest. 2022;82(5):378–84.PubMedCrossRef
55.
Diaz IM, Nocon A, Held SAE, Kobilay M, Skowasch D, Bronkhorst AJ, et al. Pre-analytical evaluation of Streck Cell-Free DNA blood collection tubes for liquid profiling in oncology. Diagnostics (Basel). 2023;13(7):1288.PubMedCrossRef
56.
Medina Diaz I, Nocon A, Mehnert DH, Fredebohm J, Diehl F, Holtrup F. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS ONE. 2016;11(11):e0166354.PubMedPubMedCentralCrossRef
57.
Heeke S, Hofman V, Benzaquen J, Otto J, Tanga V, Zahaf K, et al. Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System. (1663–9812 (Print)).
58.
Hudecova I. Digital PCR analysis of circulating nucleic acids. (1873–2933 (Electronic)).
59.
Chang L, Li J, Zhang R. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies. (1879–2561 (Electronic)).
60.
Olmedillas-López S, García-Arranz M, García-Olmo D. Current and Emerging Applications of Droplet Digital PCR in Oncology. (1179–2000 (Electronic)).
61.
Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. (1792–0981 (Print)).
62.
Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. (1557–3265 (Electronic)).
63.
Forshew T, Murtaza M Fau - Parkinson C, Parkinson C Fau - Gale D, Gale D Fau - Tsui DWY, Tsui Dw Fau - Kaper F, Kaper F Fau - Dawson S-J, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. (1946–6242 (Electronic)).
64.
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. (1546–170X (Electronic)).
65.
Imperial R, Nazer M, Ahmed Z, Kam AE, Pluard TJ, Bahaj W, et al. Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. LID - https://​doi.​org/​10.​3390/​cancers11091399. LID - 1399. (2072–6694 (Print)).
66.
Wardenaar R, Liu H Fau - Colot V, Colot V Fau - Colomé-Tatché M, Colomé-Tatché M Fau - Johannes F, Johannes F. Evaluation of MeDIP-chip in the context of whole-genome bisulfite sequencing (WGBS-seq) in Arabidopsis. (1940–6029 (Electronic)).
67.
McGuire AL, Caulfield T Fau - Cho MK, Cho MK. Research ethics and the challenge of whole-genome sequencing. (1471–0064 (Electronic)).
68.
Hon GC, Hawkins Rd Fau - Caballero OL, Caballero Ol Fau - Lo C, Lo C Fau - Lister R, Lister R Fau - Pelizzola M, Pelizzola M Fau - Valsesia A, et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. (1549–5469 (Electronic)).
69.
Ghosh RK, Pandey T, Dey P. Liquid biopsy: A new avenue in pathology. Cytopathology. 2019;30(2):138–43.PubMedCrossRef
70.
71.
Yao L, Shen H, Laird PW, Farnham PJ, Berman BP. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. Genome Biol. 2015;16(1):105.PubMedPubMedCentralCrossRef
72.
73.
Ren J, Liu Y, Zhu X, Wang X, Li Y, Liu Y, et al. OCRFinder: a noise-tolerance machine learning method for accurately estimating open chromatin regions. Front Genet. 2023;14:1184744.PubMedPubMedCentralCrossRef
74.
Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146.
75.
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–14.PubMedCrossRef
76.
Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A. 2013;110(52):21083–8.ADSPubMedPubMedCentralCrossRef
77.
Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E, et al. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol. 2015;17(7):539–46.PubMedPubMedCentralCrossRef
78.
79.
Assaf C, Hummel M Fau - Dippel E, Dippel E Fau - Goerdt S, Goerdt S Fau - Müller HH, Müller Hh Fau - Anagnostopoulos I, Anagnostopoulos I Fau - Orfanos CE, et al. High detection rate of T-cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the GeneScan technique and DNA sequencing. (0006–4971 (Print)).
80.
Pu Q, Qiao J, Liu Y, Cao X, Tan R, Yan D, et al. Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles. Front Immunol. 2022;13:1008695.PubMedPubMedCentralCrossRef
81.
Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110(2):670–7.PubMedCrossRef
82.
Damm-Welk C, Kutscher N, Zimmermann M, Attarbaschi A, Schieferstein J, Knorr F, et al. Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma. Haematologica. 2020;105(8):2141–9.PubMedPubMedCentralCrossRef
83.
Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial. Cancers (Basel). 2020;12(10):2747.PubMedCrossRef
84.
Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J Clin Oncol. 2009;27(21):3533–9.PubMedPubMedCentralCrossRef
85.
Gauthier J, Holmberg L, Wu D, Bensinger W, Gopal AK, Press O, et al. Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas. Bone Marrow Transplant. 2016;51(12):1617–9.PubMedCrossRef
86.
Kalinova M, Krskova L, Brizova H, Kabickova E, Kepak T, Kodet R. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma–residual disease monitoring and a correlation with the disease status. Leuk Res. 2008;32(1):25–32.PubMedCrossRef
87.
Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334–7.PubMedCrossRef
88.
Rigaud C, Abbas R, Grand D, Minard-Colin V, Aladjidi N, Buchbinder N, et al. Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease? Pediatr Blood Cancer. 2021;68(6):e28982.PubMedCrossRef
89.
Pokorna P, Lakka Klement G, Vasikova A, Kanderova V, Jezova M, Noskova K, et al. Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. JCO Precis Oncol. 2022;6:e2100525.PubMedPubMedCentralCrossRef
90.
Wolfe JT, Chooback L, Finn DT, Jaworsky C, Rook AH, Lessin SR. Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor. J Clin Oncol. 1995;13(7):1751–7.PubMedCrossRef
91.
Tembhare P, Yuan CM, Morris JC, Janik JE, Filie AC, Stetler-Stevenson M. Flow cytometric immunophenotypic assessment of T-cell clonality by vbeta repertoire analysis in fine-needle aspirates and cerebrospinal fluid. Am J Clin Pathol. 2012;137(2):220–6.PubMedCrossRef
92.
Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, et al. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol. 2010;133(4):592–601.PubMedCrossRef
93.
Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D, et al. Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy. Am J Clin Pathol. 2011;135(6):890–900.PubMedCrossRef
94.
Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012;4(134):134ra63.PubMedCrossRef
95.
Weng WK, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med. 2013;5(214):214ra171.PubMedCrossRef
96.
Sun C, Liao W, Deng Z, Li E, Feng Q, Lei J, et al. The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2017;96(29): e7513.PubMedCrossRef
97.
Pu Q, Qiao J, Liu Y, Cao X, Tan R, Yan D, et al. Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles. Front Immunol. 2022;13:1008695.PubMedPubMedCentralCrossRef
98.
Cerón R, Martínez A, Ramos C, De la Cruz A, García A, Mendoza I, et al. Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival. Onco Targets Ther. 2022;15:1583–95.PubMedPubMedCentralCrossRef
99.
Su Z, Wang Z, Ni X, Duan J, Gao Y, Zhuo M, et al. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. Clin Cancer Res. 2019;25(16):5049–60.PubMedCrossRef
100.
Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J Clin Oncol. 2009;27(21):3533–9.PubMedPubMedCentralCrossRef
101.
Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334–7.PubMedCrossRef
102.
Tan SJ, Yobas L, Lee GY, Ong CN, Lim CT. Microdevice for the isolation and enumeration of cancer cells from blood. Biomed Microdevices. 2009;11(4):883–92.PubMedCrossRef
103.
Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69(7):2912–8.PubMedCrossRef
104.
Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012;9(1):016001.ADSPubMedPubMedCentralCrossRef
105.
Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010;16(20):5011–8.PubMedPubMedCentralCrossRef
106.
Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003;162:149–55.PubMedCrossRef
107.
Alix-Panabières C, Vendrell JP, Pellé O, Rebillard X, Riethdorf S, Müller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007;53(3):537–9.PubMedCrossRef
108.
Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2014;134(10):2284–93.PubMedCrossRef
109.
Tkaczuk KH, Goloubeva O, Tait NS, Feldman F, Tan M, Lum ZP, et al. The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method. Breast Cancer Res Treat. 2008;111(2):355–64.PubMedCrossRef
110.
Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A, et al. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng. 2009;102(2):521–34.PubMedPubMedCentralCrossRef
111.
Hayflick L. Mortality and immortality at the cellular level. A review Biochemistry (Mosc). 1997;62(11):1180–90.PubMed
112.
Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999;59(3):551–7.PubMed
113.
Zhang W, Duan X, Zhang Z, Yang Z, Zhao C, Liang C, et al. Combination of CT and telomerase+ circulating tumor cells improves diagnosis of small pulmonary nodules. JCI Insight. 2021;6(11):e148182.
114.
Zhai TT, Ye D, Zhang QW, Wu ZQ, Xia XH. Highly Efficient Capture and Electrochemical Release of Circulating Tumor Cells by Using Aptamers Modified Gold Nanowire Arrays. ACS Appl Mater Interfaces. 2017;9(40):34706–14.PubMedCrossRef
115.
Li W, Reátegui E, Park MH, Castleberry S, Deng JZ, Hsu B, et al. Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. Biomaterials. 2015;65:93–102.PubMedPubMedCentralCrossRef
116.
Parker SG, Yang Y, Ciampi S, Gupta B, Kimpton K, Mansfeld FM, et al. A photoelectrochemical platform for the capture and release of rare single cells. Nat Commun. 2018;9(1):2288.ADSPubMedPubMedCentralCrossRef
117.
Lv SW, Liu Y, Xie M, Wang J, Yan XW, Li Z, et al. Near-Infrared Light-Responsive Hydrogel for Specific Recognition and Photothermal Site-Release of Circulating Tumor Cells. ACS Nano. 2016;10(6):6201–10.PubMedCrossRef
118.
Assaf C, Hummel M Fau - Dippel E, Dippel E Fau - Goerdt S, Goerdt S Fau - Müller HH, Müller Hh Fau - Anagnostopoulos I, Anagnostopoulos I Fau - Orfanos CE, et al. High detection rate of T-cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the GeneScan technique and DNA sequencing. (0006–4971 (Print)).
119.
Xiao W, Ren L, Chen Z, Fang LT, Zhao Y, Lack J, et al. Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat Biotechnol. 2021;39(9):1141–50.PubMedPubMedCentralCrossRef
120.
Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, et al. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol. 2010;133(4):592–601.PubMedCrossRef
121.
Tembhare P, Yuan CM, Morris JC, Janik JE, Filie AC, Stetler-Stevenson M. Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid. Am J Clin Pathol. 2012;137(2):220–6.PubMedCrossRef
122.
Canellas MC, Bruno-Riscarolli E, Ferreira-Facio CS, Lopes-Alves DV, Botafogo VD, Sutter D, et al. Immunophenotypic shifts during minimal residual evaluation in a case of leukemic form of anaplastic large cell lymphoma ALK. Cancer Rep (Hoboken). 2022;5(7):e1526.PubMedCrossRef
123.
Garcés JJ, Cedena MT, Puig N, Burgos L, Perez JJ, Cordon L, et al. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. J Clin Oncol. 2022;40(27):3151–61.PubMedCrossRef
124.
Xu M, Liu H, Liu Y, Ma X, Qiu H, Fu C, et al. Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2744–53.PubMedCrossRef
125.
Epstein Ma Fau - Achong BG, Achong Bg Fau - Barr YM, Barr YM. Virus particles in cultured lymphoblasts from burkitt's lymphoma. (0140–6736 (Print)).
126.
127.
Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. (1474–547X (Electronic)).
128.
Tan R, Phua SKA, Soong YL, Oon LLE, Chan KS, Lucky SS, et al. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun (Lond). 2020;40(11):564–85.PubMedCrossRef
129.
Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XA-OX, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). (1527–7755 (Electronic)).
130.
Kwong YA-O, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. (1528–0020 (Electronic)).
131.
Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–22.PubMedCrossRef
132.
Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002;8(1):29–34.PubMed
133.
Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–9.PubMedCrossRef
134.
Kwong YL, Pang AW, Leung AY, Chim CS, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28(4):865–70.PubMedCrossRef
135.
Wang XX, Li PF, Bai B, Gao Y, Rong QX, Cai QQ, et al. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol. Leuk Lymphoma. 2019;60(8):1917–25.PubMedCrossRef
136.
Zhao D, Hu S, Zhou D, Zhang Y, Wang W, Zhang W. Clinical Significance of Plasma Epstein-Barr Virus DNA in Peripheral T-Cell Lymphomas. Acta Haematol. 2022;145(2):132–43.PubMedCrossRef
137.
Suwiwat S, Pradutkanchana J, Ishida T, Mitarnun W. Quantitative analysis of cell-free Epstein-Barr virus DNA in the plasma of patients with peripheral T-cell and NK-cell lymphomas and peripheral T-cell proliferative diseases. J Clin Virol. 2007;40(4):277–83.PubMedCrossRef
138.
Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594–602.PubMedPubMedCentralCrossRef
139.
Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120(10):2003–10.PubMedCrossRef
140.
Wang L, Wang H, Wang JH, Xia ZJ, Lu Y, Huang HQ, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317–26.PubMedPubMedCentralCrossRef
141.
Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002;8(1):29–34.PubMed
142.
Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–9.PubMedCrossRef
143.
Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120(10):2003–10.PubMedCrossRef
144.
Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, et al. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18(13):3637–47.PubMedCrossRef
145.
146.
Wang L, Wang H, Wang JH, Xia ZJ, Lu Y, Huang HQ, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317–26.PubMedPubMedCentralCrossRef
147.
Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000;111(1):239–46.PubMed
148.
Wang XX, Li PF, Bai B, Gao Y, Rong QX, Cai QQ, et al. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol. Leuk Lymphoma. 2019;60(8):1917–25.PubMedCrossRef
149.
Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94(21):1614–9.PubMedCrossRef
150.
Hou X, Zhao C, Guo Y, Han F, Lu LX, Wu SX, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol). 2011;23(2):128–33.PubMedCrossRef
151.
Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63(9):2028–32.PubMed
152.
Jiang SY, Yang JW, Shao JB, Liao XL, Lu ZH, Jiang H. Real-time polymerase chain reaction for diagnosing infectious mononucleosis in pediatric patients: A systematic review and meta-analysis. (1096–9071 (Electronic)).
153.
Vasudevan HN, Yom SS. Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus. Hematol Oncol Clin North Am. 2021;35(5):963–71.PubMedCrossRef
154.
Lam WKJ, Jiang P, Chan KCA, Cheng SH, Zhang H, Peng W, et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2018;115(22):E5115–24.PubMedPubMedCentralCrossRef
155.
Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59(6):1188–91.PubMed
156.
Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol. 2019;1168:9–30.PubMedCrossRef
157.
Lam WKJ, Jiang P, Chan KCA, Peng W, Shang H, Heung MMS, et al. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nat Commun. 2019;10(1):3256.ADSPubMedPubMedCentralCrossRef
158.
Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res. 2011;10(1):85–96.PubMedCrossRef
159.
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817-26.e2.PubMedCrossRef
160.
Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, et al. Identification of candidate IgG biomarkers for Alzheimer’s disease via combinatorial library screening. Cell. 2011;144(1):132–42.PubMedPubMedCentralCrossRef
161.
Ballew JT, Murray JA, Collin P, Mäki M, Kagnoff MF, Kaukinen K, et al. Antibody biomarker discovery through in vitro directed evolution of consensus recognition epitopes. Proc Natl Acad Sci U S A. 2013;110(48):19330–5.ADSPubMedPubMedCentralCrossRef
162.
163.
Mussolin L, Bonvini P, Ait-Tahar K, Pillon M, Tridello G, Buffardi S, et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia. 2009;23(2):400–2.PubMedCrossRef
164.
Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27(2):416–22.PubMedCrossRef
165.
Iijima-Yamashita Y, Mori T, Nakazawa A, Fukano R, Takimoto T, Tsurusawa M, et al. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. Int J Hematol. 2018;107(2):244–50.PubMedCrossRef
166.
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–4.ADSPubMedPubMedCentralCrossRef
167.
Zaenker P, Gray ES, Ziman MR. Autoantibody Production in Cancer-The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmun Rev. 2016;15(5):477–83.PubMedCrossRef
168.
Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001;114(4):741–60.PubMedCrossRef
169.
Mussolin L, Bonvini P, Ait-Tahar K, Pillon M, Tridello G, Buffardi S, et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia. 2009;23(2):400–2.PubMedCrossRef
170.
171.
172.
Xia J, Shi J, Wang P, Song C, Wang K, Zhang J, et al. Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis. Scand J Immunol. 2016;83(6):393–408.PubMedCrossRef
173.
Frangiamone M, Cimbalo A, Alonso-Garrido M, Vila-Donat P, Manyes L. In vitro and in vivo evaluation of AFB1 and OTA-toxicity through immunofluorescence and flow cytometry techniques: A systematic review. Food Chem Toxicol. 2022;160:112798.PubMedCrossRef
174.
Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021;8(15):e2004433.PubMedCrossRef
175.
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72(1):66–75.PubMedCrossRef
176.
177.
178.
Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005;180(1):11–7.PubMedCrossRef
179.
180.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.PubMedCrossRef
181.
Ni M, Qin B, Xie L, Zhang X, Yang J, Lv H, et al. IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4. Biomed Res Int. 2018;2018:2606834.PubMedPubMedCentralCrossRef
182.
Huo J, Fu L, Jin M, Li Z, Zhang M. IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4. Invest New Drugs. 2022;40(3):537–45.PubMedCrossRef
183.
Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol. 2006;77(3):217–25.PubMedCrossRef
184.
Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, et al. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz). 2010;58(2):131–41.PubMedCrossRef
185.
Ni M, Qin B, Xie L, Zhang X, Yang J, Lv H, et al. IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4. Biomed Res Int. 2018;2018:2606834.PubMedPubMedCentralCrossRef
186.
Huo J, Fu L, Jin M, Li Z, Zhang M. IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4. Invest New Drugs. 2022;40(3):537–45.PubMedCrossRef
187.
Liu G, Qi M, Hutchinson MR, Yang G, Goldys EM. Recent advances in cytokine detection by immunosensing. Biosens Bioelectron. 2016;79:810–21.PubMedCrossRef
188.
189.
Shankar G, Cohen DA. Enhanced cytokine detection by a novel cell culture-based ELISA. J Immunoassay. 1997;18(4):371–88.PubMedCrossRef
190.
Saito K, Kobayashi D, Sasaki M, Araake H, Kida T, Yagihashi A, et al. Detection of human serum tumor necrosis factor-alpha in healthy donors, using a highly sensitive immuno-PCR assay. Clin Chem. 1999;45(5):665–9.PubMedCrossRef
191.
Koshiol J, Sklavos M Fau - Wentzensen N, Wentzensen N Fau - Kemp T, Kemp T Fau - Schiffman M, Schiffman M Fau - Dunn ST, Dunn St Fau - Wang SS, et al. Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study. (1097–0215 (Electronic)).
192.
Freer G. Intracellular staining and detection of cytokines by fluorescence-activated flow cytometry. (1940–6029 (Electronic)).
193.
Qiu JG, Mei Xl Fau - Chen Z-S, Chen Zs Fau - Shi Z, Shi Z. Cytokine detection by flow cytometry. (1940–6029 (Electronic)).
194.
Spitzer MH, Nolan GP. Mass Cytometry: Single Cells. Many Features Cell. 2016;165(4):780–91.PubMed
195.
Bjornson ZB, Nolan GP, Fantl WJ. Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol. 2013;25(4):484–94.PubMedCrossRef
196.
Leipold MD, Maecker HT. Mass cytometry: protocol for daily tuning and running cell samples on a CyTOF mass cytometer. J Vis Exp. 2012;69:e4398.
197.
Hall SA, Stucke D, Morrone B, Lebelt D, Zanella AJ. Simultaneous detection and quantification of six equine cytokines in plasma using a fluorescent microsphere immunoassay (FMIA). MethodsX. 2015;2:241–8.PubMedPubMedCentralCrossRef
198.
Cohen N, Sabhachandani P, Golberg A, Konry T. Approaching near real-time biosensing: microfluidic microsphere based biosensor for real-time analyte detection. Biosens Bioelectron. 2015;66:454–60.PubMedCrossRef
199.
Qiu L, Wimmers F, Weiden J, Heus HA, Tel J, Figdor CG. A membrane-anchored aptamer sensor for probing IFNγ secretion by single cells. Chem Commun (Camb). 2017;53(57):8066–9.PubMedCrossRef
200.
Ni S, Shen Z, Zhang P, Liu G. Enhanced performance of an electrochemical aptasensor for real-time detection of vascular endothelial growth factor (VEGF) by nanofabrication and ratiometric measurement. Anal Chim Acta. 2020;1121:74–82.PubMedCrossRef
201.
202.
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.PubMedCrossRef
203.
Okamura R, Piccioni DE, Boichard A, Lee S, Jimenez RE, Sicklick JK, et al. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. Int J Cancer. 2021;148(11):2839–47.PubMedPubMedCentralCrossRef
204.
Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928–37.PubMedPubMedCentralCrossRef
205.
Cheng X, Zhang L, Chen Y, Qing C. Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer. J Ovarian Res. 2017;10(1):75.PubMedPubMedCentralCrossRef
206.
Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021;11(4):858–73.PubMedCrossRef
207.
Heidrich I, Ačkar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: Potential and challenges. Int J Cancer. 2021;148(3):528–45.PubMedCrossRef
208.
Hou J, Li X, Xie KP. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol Cancer. 2021;20(1):34.PubMedPubMedCentralCrossRef
209.
Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol Med. 2021;27(5):482–500.PubMedCrossRef
210.
211.
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. (1365–2141 (Electronic)).
212.
Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M, et al. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Breast Cancer. 2016;23(1):120–7.PubMedCrossRef
213.
Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol. 2018;4(5):717–21.PubMedPubMedCentralCrossRef
214.
Seale KN, Tkaczuk KHR. Circulating Biomarkers in Breast Cancer. Clin Breast Cancer. 2022;22(3):e319–31.PubMedCrossRef
215.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–48.PubMedPubMedCentralCrossRef
216.
Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148–51.PubMedPubMedCentralCrossRef
217.
Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology. 2007;50(4):498–508.PubMedCrossRef
218.
Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91(6):2076–84.PubMedCrossRef
219.
Larose H, Prokoph N, Matthews JD, Schlederer M, Högler S, Alsulami AF, et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2021;106(6):1693–704.PubMedCrossRef
220.
Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, et al. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia. 2021;35(5):1500–5.PubMedCrossRef
221.
Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186(3):e28–31.PubMedPubMedCentralCrossRef
222.
Sánchez-Beato M, Méndez M, Guirado M, Pedrosa L, Sequero S, Yanguas-Casás N, et al. A genetic profiling guideline to support diagnosis and clinical management of lymphomas. Clin Transl Oncol. 2023. Epub ahead of print.
223.
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23.PubMedPubMedCentralCrossRef
224.
Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664–76.PubMedPubMedCentralCrossRef
Metadata
Title
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Authors
Zongyao Huang
Yao Fu
Hong Yang
Yehan Zhou
Min Shi
Qingyun Li
Weiping Liu
Junheng Liang
Liuqing Zhu
Sheng Qin
Huangming Hong
Yang Liu
Publication date
17-02-2024
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-024-01947-7

Other articles of this Issue 1/2024

Molecular Cancer 1/2024 Go to the issue

Research

CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis

Review

The senescence journey in cancer immunoediting

Review

Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance

Correction

Correction: CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer

Research

Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway

Review

tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits